Private Company Drug Development Roundup

22 May 2017

This report focuses on key upcoming catalysts for private drug development companies across multiple indications.

Included in this report:

Investigative News
  • Oncoceutics’ early glioblastoma data sparks expert support, while company explores strategic options
  • Stealth’s Phase II mitochondrial disease extension trial spurs physician enthusiasm for elamipretide sustained efficacy, clinical significance uncertain
  • Stealth BioTherapeutics’ planned Phase III trial divides physicians over potential elamipretide protocol length, functional endpoints desired
  • Melinta’s delafloxacin Phase III efficacy data supports approval for ABSSSI, fluoroquinolonerelated side effects could blunt uptake – experts
  • Protagonist’s PTG-100 has uncertain Phase IIb success forecasts in UC, possible infection concerns raised – experts
Data Analysis
  • Number of Drug Candidates Currently in Clinical Development by Private Companies Split by the Region In Which the Company is Headquartered
  • Largest Drug or Biologic Licensing Deals Involving a Private Company in 1Q17